CN116474076A - 用于肌少症防治的组合物及制剂 - Google Patents
用于肌少症防治的组合物及制剂 Download PDFInfo
- Publication number
- CN116474076A CN116474076A CN202310544262.3A CN202310544262A CN116474076A CN 116474076 A CN116474076 A CN 116474076A CN 202310544262 A CN202310544262 A CN 202310544262A CN 116474076 A CN116474076 A CN 116474076A
- Authority
- CN
- China
- Prior art keywords
- parts
- vitamin
- composition
- sarcopenia
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- 208000001076 sarcopenia Diseases 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title abstract description 7
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims abstract description 38
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 21
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
- 235000021119 whey protein Nutrition 0.000 claims abstract description 20
- 240000008042 Zea mays Species 0.000 claims abstract description 19
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 19
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 19
- 235000005822 corn Nutrition 0.000 claims abstract description 19
- 229960003624 creatine Drugs 0.000 claims abstract description 19
- 239000006046 creatine Substances 0.000 claims abstract description 19
- 239000011575 calcium Substances 0.000 claims abstract description 18
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 18
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940069445 licorice extract Drugs 0.000 claims abstract description 17
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 claims abstract description 17
- 229940088594 vitamin Drugs 0.000 claims abstract description 16
- 229930003231 vitamin Natural products 0.000 claims abstract description 16
- 235000013343 vitamin Nutrition 0.000 claims abstract description 16
- 239000011782 vitamin Substances 0.000 claims abstract description 16
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 14
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 14
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims abstract description 13
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 30
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 28
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 26
- 238000009472 formulation Methods 0.000 claims description 20
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 19
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 19
- 235000005282 vitamin D3 Nutrition 0.000 claims description 19
- 239000011647 vitamin D3 Substances 0.000 claims description 19
- 229940021056 vitamin d3 Drugs 0.000 claims description 19
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 17
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 claims description 16
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 claims description 16
- 235000019143 vitamin K2 Nutrition 0.000 claims description 16
- 239000011728 vitamin K2 Substances 0.000 claims description 16
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 15
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 15
- 229930003451 Vitamin B1 Natural products 0.000 claims description 15
- 229930003471 Vitamin B2 Natural products 0.000 claims description 15
- 230000002265 prevention Effects 0.000 claims description 15
- 229960002477 riboflavin Drugs 0.000 claims description 15
- 229960003495 thiamine Drugs 0.000 claims description 15
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 15
- 235000010374 vitamin B1 Nutrition 0.000 claims description 15
- 239000011691 vitamin B1 Substances 0.000 claims description 15
- 235000019164 vitamin B2 Nutrition 0.000 claims description 15
- 239000011716 vitamin B2 Substances 0.000 claims description 15
- 235000019158 vitamin B6 Nutrition 0.000 claims description 15
- 239000011726 vitamin B6 Substances 0.000 claims description 15
- 229940011671 vitamin b6 Drugs 0.000 claims description 15
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 14
- 229960003080 taurine Drugs 0.000 claims description 14
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 claims description 13
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 13
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 13
- 235000019152 folic acid Nutrition 0.000 claims description 13
- 239000011724 folic acid Substances 0.000 claims description 13
- 229960000304 folic acid Drugs 0.000 claims description 13
- 239000011777 magnesium Substances 0.000 claims description 13
- 229910052749 magnesium Inorganic materials 0.000 claims description 13
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 claims description 13
- 229940096998 ursolic acid Drugs 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 12
- 235000019156 vitamin B Nutrition 0.000 claims description 10
- 239000011720 vitamin B Substances 0.000 claims description 10
- 244000062241 Kaempferia galanga Species 0.000 claims description 9
- 235000013421 Kaempferia galanga Nutrition 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000001243 protein synthesis Methods 0.000 abstract description 15
- 108090000623 proteins and genes Proteins 0.000 abstract description 15
- 230000014616 translation Effects 0.000 abstract description 15
- 102000004169 proteins and genes Human genes 0.000 abstract description 14
- 235000018102 proteins Nutrition 0.000 abstract description 13
- 235000001014 amino acid Nutrition 0.000 abstract description 11
- 150000001413 amino acids Chemical class 0.000 abstract description 11
- 238000010521 absorption reaction Methods 0.000 abstract description 6
- 230000029087 digestion Effects 0.000 abstract description 5
- 239000013589 supplement Substances 0.000 abstract description 3
- 239000000419 plant extract Substances 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 22
- 230000001737 promoting effect Effects 0.000 description 21
- 210000003205 muscle Anatomy 0.000 description 14
- 230000006870 function Effects 0.000 description 12
- 230000004060 metabolic process Effects 0.000 description 12
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 210000000988 bone and bone Anatomy 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 210000002027 skeletal muscle Anatomy 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000008934 Muscle Proteins Human genes 0.000 description 5
- 108010074084 Muscle Proteins Proteins 0.000 description 5
- 230000009102 absorption Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 4
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 244000139693 Arctostaphylos uva ursi Species 0.000 description 3
- 235000012871 Arctostaphylos uva ursi Nutrition 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000009469 supplementation Effects 0.000 description 3
- 238000003809 water extraction Methods 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 244000131316 Panax pseudoginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 230000007661 gastrointestinal function Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 230000004220 muscle function Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- -1 nitrogenous organic acid Chemical class 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- 210000002363 skeletal muscle cell Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical group C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical group C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000208421 Ericaceae Species 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 1
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 1
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- WLJUMPWVUPNXMF-UHFFFAOYSA-L calcium;3-hydroxy-3-methylbutanoate Chemical compound [Ca+2].CC(C)(O)CC([O-])=O.CC(C)(O)CC([O-])=O WLJUMPWVUPNXMF-UHFFFAOYSA-L 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- CCRCUPLGCSFEDV-UHFFFAOYSA-N cinnamic acid methyl ester Natural products COC(=O)C=CC1=CC=CC=C1 CCRCUPLGCSFEDV-UHFFFAOYSA-N 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002614 leucines Chemical class 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000000695 menaquinone group Chemical group 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- CCRCUPLGCSFEDV-BQYQJAHWSA-N methyl trans-cinnamate Chemical compound COC(=O)\C=C\C1=CC=CC=C1 CCRCUPLGCSFEDV-BQYQJAHWSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004898 mitochondrial function Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000037257 muscle growth Effects 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000004070 myogenic differentiation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical class [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229960003581 pyridoxal Drugs 0.000 description 1
- 235000008164 pyridoxal Nutrition 0.000 description 1
- 239000011674 pyridoxal Substances 0.000 description 1
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 1
- WHOMFKWHIQZTHY-UHFFFAOYSA-L pyridoxine 5'-phosphate(2-) Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(CO)=C1O WHOMFKWHIQZTHY-UHFFFAOYSA-L 0.000 description 1
- 235000019170 pyridoxine-5-phosphate Nutrition 0.000 description 1
- 239000011763 pyridoxine-5-phosphate Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000004916 vomit Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Marine Sciences & Fisheries (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一种用于肌少症防治的组合物及制剂,属于治疗肌少症技术领域。组合物按重量份数计包括:玉米肽20~60份、乳清蛋白100~150份、β‑羟基β‑甲基丁酸钙10~30份、肌酸10~30、维生素0.04~0.15份、葛根素6~15份、人参皂苷0.8~1.2份以及甘草提取物2~4份。其补充容易吸收的蛋白质、氨基酸和维生素类,结合植物提取物的添加,能够促进消化吸收、促进蛋白质合成,从而能够有效地防治肌少症。
Description
技术领域
本申请涉及治疗肌少症技术领域,具体而言,涉及一种用于肌少症防治的组合物及制剂。
背景技术
肌少症是一种与老年人增龄相关的肌肉质量和力量下降并伴随身体活动功能降低的一种常见性老年疾病。随着老龄化的增长,肌少症发病率逐年攀升,可导致患者日常生活能力和质量下降、死亡风险增加等不良后果。
临床目前鲜见可以根治肌少症的药物,且药物干预存在一定程度副作用。对于预防及治疗肌少症方面主要采用抗阻力量运动与蛋白质营养补充为主,但本申请的发明人发现,老年人群消化吸收机能下降和蛋白质合成利用率低等特点,仅仅提供蛋白质及氨基酸原料难以达到效果,应结合改善老年人群的消化吸收及代谢能力。
发明内容
本申请提供了一种用于肌少症防治的组合物及制剂,其补充容易吸收的蛋白质、氨基酸和维生素类,结合植物提取物的添加,能够促进消化吸收、促进蛋白质合成,从而能够有效地防治肌少症。
本申请是这样实现的:
第一方面,本申请提供一种用于肌少症防治的组合物,按重量份数计,其包括:
玉米肽20~60份、乳清蛋白100~150份、β-羟基β-甲基丁酸钙10~30份、肌酸10~30、维生素0.04~0.15份、葛根素6~15份、人参皂苷0.8~1.2份以及甘草提取物2~4份。
进一步地,维生素包括B族维生素、维生素D3和维生素K2。
进一步地,B族维生素、维生素D3和维生素K2的重量比为4~13:0.01~0.02:0.03~0.05。
进一步地,B族维生素包括维生素B1、维生素B2、维生素B6和叶酸。
进一步地,维生素B1、维生素B2、维生素B6和叶酸的重量比为2~6:1~3:1~3:0.1~0.15。
进一步地,组合物还包括牛磺酸2.5~3.5重量份。
进一步地,组合物还包括4~8重量份的钙和2~6重量份的镁。
进一步地,组合物还包括4~6重量份的熊果酸。
进一步地,组合物还包括0.008~0.016重量份的高良姜提取物。
第二方面,本申请提供一种用于肌少症防治的制剂,其由第一方面的用于肌少症防治的组合物制成,制剂为片剂、粉剂、丸剂或胶囊剂。
本申请实施例的用于肌少症防治的组合物及制剂的有益效果至少如下:
玉米肽、乳清蛋白作为合成骨骼肌蛋白质原料,容易消化吸收,所含必需氨基酸种类齐全,且含有丰富的亮氨酸,该氨基酸在体内有类似合成类激素胰岛素的功效,也有助于促进蛋白质合成信号蛋白的表达;β-羟基β-甲基丁酸钙是亮氨酸代谢的中间产物,有着重要的促进合成蛋白质作用,并有抑制蛋白质降解的功效;肌酸也有促进蛋白质合成作用,能进一步增强蛋白质合成效果,有助于克服或对抗“老年蛋白质合成抵抗”。维生素类是保证机体正常代谢所需,也有助于促进蛋白质合成,与蛋白质、氨基酸的补充有协同增效作用。该组合物中的葛根素具有活血化瘀、改善微循环、扩张冠状动脉和脑血管、降低心肌耗氧量等作用;人参皂苷、甘草提取物等具有抗氧化抗炎及促合成的功效等,对于改善老年肌少症人群免疫机能、调节胃肠机能,促进营养物质的吸收利用,对玉米肽、乳清蛋白、β-羟基β-甲基丁酸钙、肌酸、维生素等营养物质的利用有促进作用,各组分配比合适,从而能够有效地防治肌少症。
具体实施方式
下面将结合实施例对本申请的实施方案进行详细描述,但是本领域技术人员将会理解,下列实施例仅用于说明本申请,而不应视为限制本申请的范围。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
以下针对本申请实施例的用于肌少症防治的组合物及制剂进行具体说明:
第一方面,本申请提供一种用于肌少症防治的组合物,按重量份数计,其包括:
玉米肽20~60份、乳清蛋白100~150份、β-羟基β-甲基丁酸钙10~30份、肌酸10~30、维生素0.04~0.15份、葛根素6~15份、人参皂苷0.8~1.2份以及甘草提取物2~4份。
玉米肽是从玉米中提取的蛋白质,经过定向酶切及特定小肽分离技术获得的一类分子量小且活性高的肽类物质,其水溶性好且易被人体吸收,具有抗氧化、抗疲劳、降血压以及保肝等功能。通用的方法是对玉米蛋白进行酶水解而获得玉米活性肽。可选地,按重量份数计,组合物中的玉米肽为20份、30份、40份、50份或60份。
乳清蛋白是乳清蛋白酶解后肽段和氨基酸的混合物,具有多种对人体有益的生物学功能。乳清蛋白生物活性肽的生产方法主要有酶解法、发酵法和重组DNA技术。其工业生产主要方法为酶解法,包括以下步骤:(1)乳清蛋白与脂肪、乳糖等物质分离;(2)乳清蛋白酶水解,使用的酶主要有动物来源的酶,如胰蛋白酶、胃蛋白酶,或植物酶,如木瓜蛋白酶;(3)酶解后的处理,包括过滤、离心等步骤;(4)喷雾干燥;(5)产品包装。乳清蛋白源生物活性肽具有抗氧化、调血糖、抗高血压、抗菌、免疫调节等作用。可选地,按重量份数计,组合物中的乳清蛋白为100份、110份、120份、130份、140份或150份。
玉米肽、乳清蛋白作为合成骨骼肌蛋白质原料,容易消化吸收,所含必需氨基酸种类齐全,且含有丰富的亮氨酸,该氨基酸在体内有类似合成类激素胰岛素的功效,也有助于促进蛋白质合成信号蛋白的表达。
β-羟基-β-甲基丁酸盐(HMB)是亮氨酸的活性代谢产物,在体内有5%~10%的亮氨酸转化为HMB,具有促进肌肉蛋白合成代谢的效果。大多数病理情况下,如严重创伤、慢性阻塞性肺疾病、肿瘤恶病质、艾滋病等,补充HMB均可预防肌肉消耗。β-羟基-β-甲基丁酸盐能够通过上调合成代谢信号通路和下调分解代谢信号通路而刺激蛋白质合成,发挥肌肉保护作用。可选地,按重量份数计,组合物中的β-羟基β-甲基丁酸钙为10份、15份、20份、25份或30份。
肌酸是一种含氮的有机酸,在体内天然存在,在肝、肾中由精氨酸、甲硫氨酸和甘氨酸合成,约98%肌酸在骨骼肌中存储和被利用。补充肌酸可增加骨矿物质含量,促进蛋白质合成作用,减少肌肉蛋白质降解和骨的再吸收。肌酸类营养补剂主要通过维持体内ATP总量、增加糖原储备、调节糖代谢、维持肌细胞酸碱稳定和刺激肌细胞增殖分化等作用机制来提高机体运动能力和恢复能力。可选地,按重量份数计,组合物中的肌酸为10份、15份、20份、25份或30份。
维生素类是保证机体正常代谢所需,也有助于促进蛋白质合成,与蛋白质、氨基酸的补充有协同增效作用。
进一步地,维生素包括B族维生素、维生素D3和维生素K2。
维生素D3是存在于动物体组织及鱼肝油中的胆钙化醇,维生素D3在机体内的活性形式是1,25-(OH)2-D3,动物骨骼肌细胞中存在着能与它特异结合的受体。维生素D3可提高人体内血钙及血磷水平,促进旧骨释放磷酸钙,促进成骨细胞的功能及骨样组织成熟,促进骨骼钙化。
维生素K2是一类具有甲基萘醌结构的脂溶性维生素,维生素D3和维生素K2对于维持老年人该类维生素营养水平是必需的,且维生素D3和维生素K2对于骨骼肌质量的增加和肌肉力量的维持有积极作用。B族维生素类是保证机体正常代谢所需,也有助于促进蛋白质合成和氨基酸代谢。
示例性地,B族维生素、维生素D3和维生素K2的重量比为4~13:0.01~0.02:0.03~0.05。例如为4:0.01:0.03或7:0.01:0.04或10:0.02:0.03或13:0.02:0.05。
可选地,按重量份数计,组合物中的维生素D3为0.0001份、0.00012份、0.00014份、0.00016份、0.00018份或0.0002份。可选地,按重量份数计,组合物中的维生素K2为0.0003份、0.00035份、0.0004份、0.00045份或0.0005。
示例性地,B族维生素包括维生素B1、维生素B2、维生素B6和叶酸。
维生素B1的主要生理功能是参与能量代谢,维持神经、肌肉特别是心肌的正常功能,以及维持正常食欲、胃肠蠕动和消化分泌等。维生素B1是葡萄糖代谢的关键酶的辅助因子,在维持脑内氧化代谢平衡方面具有重要作用,是维持神经、心脏及消化系统正常机能的重要生物活性物质。
维生素B2的主要生理功用是作为辅酶促进代谢,主要参与的生化反应有呼吸链能量产生,氨基酸、脂类氧化,嘌呤碱转化为尿酸,芳香族化合物的羟化,蛋白质与某些激素的合成,铁的转运、储存及动员,参与叶酸、吡多醛、尼克酸的代谢等。体内维生素B2的储存是很有限的,需每天由饮食补充。
维生素B6主要以吡哆醇-5-磷酸(PLP)的形式参与蛋白质的合成和分解代谢、糖异生、不饱和脂肪酸代谢。有研究发现,肌少症老年人摄入维生素B6含量比非肌少症老年人减少10%~18%。
叶酸是细胞增殖和DNA合成与修饰所必需的B族维生素,通常以氧化形式或还原四氢叶酸形式存在,人体不能合成,需要从外界摄取。由于人体不能合成叶酸,机体叶酸水平需依靠外源性的补给,所以极易造成叶酸的缺乏。近年来,研究学者发现叶酸在预防骨质疏松中具有良好的作用效果,其能够减轻细胞的氧化应激反应,防止遗传物质被破坏,在改善同型半胱氨酸代谢的同时,进一步促进一氧化氮以及一氧化氮合酶的合成和表达,纠正破骨细胞和成骨细胞之间的偶联失调,减少骨量丢失。
可选地,维生素B1、维生素B2、维生素B6和叶酸的重量比为2~6:1~3:1~3:0.1~0.15。
示例性地,按重量份数计,组合物中的维生素B1为0.02份、0.03份、0.04份、0.05份或0.06份,维生素B2为0.01份、0.02份或0.03份,维生素B6为0.01份、0.02份或0.03份,叶酸为0.001份、0.0012份、0.0014份或、0.0015份。
另外,组合物种的葛根素是一种天然异黄酮化合物,临床上用于治疗T2DM及其并发症,证实确有降低血糖、血脂,增加机体葡萄糖稳态的作用。在本组合物中葛根素的添加,可增加骨骼肌胰岛素敏感性、线粒体功能,增加FA氧化,从而协调骨骼肌细胞对葡萄糖和脂肪酸的利用,调节机体糖脂代谢稳态。示例性地,葛根素是由葛根通过水提法获取。可选地,按重量份数计,组合物中的葛根素为6份、8份、10份、12份、14份或15份。
人参皂苷是人参的主要药理活性成分,人参皂苷Rb1具有抗疲劳、抗氧化、神经保护、抗炎和抗糖尿病等多种药理活性。特别地,人参皂苷Rb1对骨骼肌组织具有保护作用。研究表明,人参皂苷Rb1能够通过PI3K/AKT/Nrf2通路的激活来减少老化骨骼肌的氧化应激;在对成肌细胞分化的研究中,人参皂昔Rb1还能够促进肌原性分化和肌管的生长,从而预防肌肉萎缩;在术后疲劳综合征的研究中,发现人参皂苷Rb1具有有效的抗疲劳作用,且这种作用与其对能量代谢的改善有关。可选地,按重量份数计,组合物中的人参皂苷为0.8份、0.9份、1.0份、1.1份或1.2份。
甘草提取物是一种广为人知的传统中药材,其中通过水提法。可以抑制骨的重吸收,具有抗氧化、抗炎、抗菌、抗癌和抗诱变性等药用价值,在改善心脑血管疾病、老年痴呆等退行性疾病、抗糖尿病等各类疾病治疗中也发挥作用。示例性地,甘草提取物是由甘草通过水提法提取得到。可选地,按重量份数计,组合物中的甘草提取物为2份、2.5份、3份、3.5份或4份。
该组合物中的葛根素具有活血化瘀、改善微循环、扩张冠状动脉和脑血管、降低心肌耗氧量等作用;人参皂苷、甘草提取物等具有抗氧化抗炎及促合成的功效等,对于改善老年肌少症人群免疫机能、调节胃肠机能,促进营养物质的吸收利用,对玉米肽、乳清蛋白、β-羟基β-甲基丁酸钙、肌酸、维生素等营养物质的利用有促进作用,各组分配比合适,从而能够有效地防治肌少症。
进一步地,组合物还包括4~6重量份的熊果酸。熊果酸是一种五环三萜类天然化合物,是一种熊果提取物。熊果提取物以杜鹃花科植物熊果的干燥叶为原料提取,主要活性成分有熊果苷,熊果酸。大量研究发现熊果酸对肥胖、糖尿病、抗炎症、抗氧化反应及乳腺癌、肺癌等肿瘤都有作用。且熊果酸可以抑制肌肉衰老相关基因的表达从而抑制骨骼肌衰老;刺激IGF-1的表达,增强mTOR、AMPK等表达促进肌肉肥大。
可选地,按重量份数计,组合物中的熊果酸为4份、4.5份、5份5.5份和6份。
进一步地,组合物还包括0.008~0.016重量份的高良姜提取物。高良姜提取物为姜科的干燥根茎中提取,其中主要成分是1,8-桉叶素和桂皮酸甲酯。具有抗胃溃疡、止呕、促进胃排空、肠推进、降血糖和胃肠道保护等药理作用。
可选地,按重量份数计,组合物中的高良姜提取物为0.008份、0.010份、0.012份、0.014份或0.016份。
进一步地,组合物还包括牛磺酸2.5~3.5重量份。牛磺酸是一种β-氨基磺酸,是机体内含量最丰富的自由氨基酸,在肌肉细胞中的浓度很高。已有研究表明牛磺酸具有提高机体抗氧化能力、调节钙离子水平、调节氨基酸代谢等生理功能。人体补充牛磺酸,能减少体内自由基的生成,增加超氧化物歧化酶和谷胱甘肽过氧化物酶等抗氧化酶的活性,还原已生成的自由基,延缓人体衰老;牛磺酸通过对机体组织钙离子进行双向调节,来维持细胞正常生理功能,还能参与肌肉正常的舒张和伸缩功能;牛磺酸作为一种营养补充剂能提高并稳定人体内支链氨基酸的浓度,提高机体运动能力。
可选地,按重量份数计,组合物中的牛磺酸为2.5份、3份或3.5份。
进一步地,组合物还包括4~8重量份的钙和2~6重量份的镁。
钙元素几乎参与一切生命现象和细胞功能,是人体内含量较高的必需无机盐,自始至终支持着机体的生长、发育,是与机体运动能力密切相关的元素之一。人体内钙的储备主要在骨中,钙以羟基磷灰石盐的形式沉积在密质骨和松质骨内,使骨在保持人的体形、支持体重、保护人体内部器官方面起到重要作用。增加钙的摄入量对可以减缓骨质损耗,提高骨质量,在减少由骨质疏松引起的骨折率方面也有着重要作用。此外,钙离子在肌肉的收缩与兴奋过程中起着重要的调节作用,如果钙在肌肉中的平衡状态遭到破坏,便会引起骨骼肌的疼痛、抽搐以及功能的下降,也会引起体内平滑肌和心肌的不正常运动,使人体丧失平衡和协调机能。
镁与肌肉生长、质量和力量等方面有密切联系。镁元素随着年龄的增加而减少,继而可能产生肌肉无力和肌肉耐力下降,从而降低肌肉运动功能,甚至导致抽搐、痉挛等的发生,补充镁元素可保护肌少症老年人肌肉功能,从而改善运动表现。有研究表明,镁膳食可提高握力、下肢力量、踝关节伸展力以及最大等长躯干屈曲、旋转和跳跃的能力。
可选地,按重量份数计,组合物中的钙为4份、5份、6份、7份或8份,镁为2份、3份4份、5份或6份。
综上,本申请的用于肌少症防治的组合物,具有改善肌肉功能、促进肌肉蛋白质合成、抗疲劳、改善骨质量、调节代谢以及维持神经、消化等系统正常功能等作用。
第二方面,本申请提供一种用于肌少症防治的制剂,其由第一方面的用于肌少症防治的组合物制成,制剂为片剂、粉剂、丸剂或胶囊剂。
以下结合实施例对本申请的用于肌少症防治的组合物及制剂作进一步的详细描述。
实施例1
本实施例提供一种用于肌少症防治的组合物,按重量份数计,其包括:
玉米肽40份、乳清蛋白120份、β-羟基β-甲基丁酸钙20份、肌酸20份、0.0001份的维生素D3、0.0004份的维生素K2、0.04份维生素B1、0.02份的维生素B2、0.02份的维生素B6、葛根素10份、人参皂苷1份以及甘草提取物3份。
本实施例提供一种用于肌少症防治的制剂,其制备步骤包括:将上述组合物按比例混合均匀后装袋,每袋15g。
实施例2
本实施例提供一种用于肌少症防治的组合物,按重量份数计,其包括:
玉米肽40份、乳清蛋白120份、β-羟基β-甲基丁酸钙20份、肌酸20份、0.0001份的维生素D3、0.0004份的维生素K2、0.04份维生素B1、0.02份的维生素B2、0.02份的维生素B6、葛根素10份、人参皂苷1份以及甘草提取物3份、牛磺酸3份、钙5份、镁4份、熊果酸5份、高良姜提取物0.01份。
本实施例提供一种用于肌少症防治的制剂,其制备步骤包括:将上述组合物按比例混合均匀后装袋,每袋15g。
实施例3
本实施例提供一种用于肌少症防治的组合物,按重量份数计,其包括:
玉米肽60份、乳清蛋白100份、β-羟基β-甲基丁酸钙30份、肌酸30份、0.0002份的维生素D3、0.0005份的维生素K2、0.06份维生素B1、0.03份的维生素B2、0.03份的维生素B6、葛根素6份、人参皂苷1.2份以及甘草提取物4份、牛磺酸3份、钙5份、镁4份、熊果酸5份、高良姜提取物0.01份。
本实施例提供一种用于肌少症防治的制剂,其制备步骤包括:将上述组合物按比例混合均匀后装袋,每袋15g。
实施例4
本实施例提供一种用于肌少症防治的组合物,按重量份数计,其包括:
玉米肽20份、乳清蛋白150份、β-羟基β-甲基丁酸钙10份、肌酸10份、0.0002份的维生素D3、0.0003份的维生素K2、0.02份维生素B1、0.01份的维生素B2、0.01份的维生素B6、葛根素15份、人参皂苷0.8份以及甘草提取物2份、牛磺酸3份、钙5份、镁4份、熊果酸5份、高良姜提取物0.01份。
本实施例提供一种用于肌少症防治的制剂,其制备步骤包括:将上述组合物按比例混合均匀后装袋,每袋15g。
实施例5
本实施例提供一种用于肌少症防治的组合物,按重量份数计,其包括:
玉米肽20份、乳清蛋白150份、β-羟基β-甲基丁酸钙10份、肌酸10份、0.0002份的维生素D3、0.0003份的维生素K2、0.02份维生素B1、0.01份的维生素B2、0.01份的维生素B6、葛根素15份、人参皂苷0.8份以及甘草提取物2份、牛磺酸2.5份、钙8份、镁6份、熊果酸4份、高良姜提取物0.016份。
本实施例提供一种用于肌少症防治的制剂,其制备步骤包括:将上述组合物按比例混合均匀后装袋,每袋15g。
实施例6
本实施例提供一种用于肌少症防治的组合物,按重量份数计,其包括:
玉米肽20份、乳清蛋白150份、β-羟基β-甲基丁酸钙10份、肌酸10份、0.0002份的维生素D3、0.0003份的维生素K2、0.02份维生素B1、0.01份的维生素B2、0.01份的维生素B6、葛根素15份、人参皂苷0.8份以及甘草提取物2份、牛磺酸3.5份、钙4份、镁2份、熊果酸6份、高良姜提取物0.008份。
本实施例提供一种用于肌少症防治的制剂,其制备步骤包括:将上述组合物按比例混合均匀后装袋,每袋15g。
试验例1
研究设计:双盲随机化干预试验。
受试对象选择:为探讨本申请实施例的制剂的效果,我们选择20名肌少症受试对象。受试对象的基本信息如下:性别均为女性,年龄74.69±6.40岁,身高157.81±6.64cm。随机分为对照组和试验组,两组之间的年龄和身高无显著性差异。
干预方法:所有受试对象均在指定的食堂就餐,试验组每天补充2包实施例1的制剂,对照组每天补充2包豆奶粉(每包15g),分别为早餐及晚餐期间,试验共持续4周。需要说明的是,对照组的豆奶粉能量、蛋白质含量、维生素含量均与实施例1的制剂中一致,且不含葛根素、人参皂苷以及甘草提取物。其中,蛋白质来源主要是大豆蛋白。
分别测试受试对象在干预开始前和干预结束后体成分、血液营养生化指标及肌肉力量,结果如表1和表2所示。
表1.试验前后受试对象体成分及血液营养生化指标变化(平均数±标准差)
注:与对照组后比较*p<0.05;与试验前比较#p<0.05。
如表1结果显示,与试验前相比,经4周的干预后,试验组和对照组的受试者体重、体脂均未有显著变化。实施例1的制剂干预前后,肌肉量有显著性增加(P<0.05),且显著高于对照组试验后(P<0.05)。其它血液学指标中,实施例1的制剂干预后,血红蛋白、总蛋白和血清25(OH)D3有显著性增加(P<0.05)。说明实施例1的制剂提高了瘦体重质量,并改善了血清蛋白质营养水平。
表2:试验前后受试对象肌肉力量的差异(平均数±标准差)
注:与试验前比较,#P<0.05,##P<0.01;与对照组后比较,*P<0.05。
如表2结果显示,实施例1的制剂干预前后,受试者的小腿围、腿部力量、握力和背力有显著性增加,说明实施例1的制剂增强了肌肉力量。
以上仅为本申请的具体实施例而已,并不用于限制本申请,对于本领域的技术人员来说,本申请可以有各种更改和变化。凡在本申请的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本申请的保护范围之内。
Claims (10)
1.一种用于肌少症防治的组合物,其特征在于,按重量份数计,其包括:
玉米肽20~60份、乳清蛋白100~150份、β-羟基β-甲基丁酸钙10~30份、肌酸10~30、维生素0.04~0.15份、葛根素6~15份、人参皂苷0.8~1.2份以及甘草提取物2~4份。
2.根据权利要求1所述的用于肌少症防治的组合物,其特征在于,所述维生素包括B族维生素、维生素D3和维生素K2。
3.根据权利要求2所述用于肌少症防治的组合物,其特征在于,所述B族维生素、所述维生素D3和所述维生素K2的重量比为4~13:0.01~0.02:0.03~0.05。
4.根据权利要求3所述的用于肌少症防治的组合物,其特征在于,所述B族维生素包括维生素B1、维生素B2、维生素B6和叶酸。
5.根据权利要求4所述的用于肌少症防治的组合物,其特征在于,所述维生素B1、所述维生素B2、所述维生素B6和所述叶酸的重量比为2~6:1~3:1~3:0.1~0.15。
6.根据权利要求1~5任一项所述的用于肌少症防治的组合物,其特征在于,所述组合物还包括牛磺酸2.5~3.5重量份。
7.根据权利要求1~5任一项所述的用于肌少症防治的组合物,其特征在于,所述组合物还包括4~8重量份的钙和2~6重量份的镁。
8.根据权利要求1~5任一项所述的用于肌少症防治的组合物,其特征在于,所述组合物还包括4~6重量份的熊果酸。
9.根据权利要求1~5任一项所述的用于肌少症防治的组合物,其特征在于,所述组合物还包括0.008~0.016重量份的高良姜提取物。
10.一种用于肌少症防治的制剂,其特征在于,其由权利要求1~9任一项所述的用于肌少症防治的组合物制成,所述制剂为片剂、粉剂、丸剂或胶囊剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310544262.3A CN116474076A (zh) | 2023-05-15 | 2023-05-15 | 用于肌少症防治的组合物及制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310544262.3A CN116474076A (zh) | 2023-05-15 | 2023-05-15 | 用于肌少症防治的组合物及制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116474076A true CN116474076A (zh) | 2023-07-25 |
Family
ID=87226912
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310544262.3A Pending CN116474076A (zh) | 2023-05-15 | 2023-05-15 | 用于肌少症防治的组合物及制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116474076A (zh) |
-
2023
- 2023-05-15 CN CN202310544262.3A patent/CN116474076A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1427297B1 (en) | Composition for reducing appetite in mammals comprising procyanidin | |
CN108651998A (zh) | 一种具有缓解疲劳功能的乳清蛋白粉及其制备方法 | |
CN101248873A (zh) | 具有视力保护功能的饮用食品 | |
CN108719984B (zh) | 一种针对痛风人群的代餐营养棒及其制备方法 | |
AU2005316150A1 (en) | Supplement dietary composition for promoting weight loss | |
KR20010072587A (ko) | 발효유로부터 유래된 골다공증 예방용의 식이성 보충식 | |
US20050013884A1 (en) | Compositions and methods for treating heart disease | |
CN110720516A (zh) | 骨营养特膳食品及其制备方法和应用 | |
CN113349377A (zh) | 一种瘦身益生菌软胶囊及其制备方法 | |
WO2022165700A1 (zh) | 一种多肽营养粉及其制备方法 | |
CN110584120A (zh) | 骨健康组合物 | |
CN1943695A (zh) | 一种甲鱼制剂及其生产工艺 | |
CN116474076A (zh) | 用于肌少症防治的组合物及制剂 | |
KR20200043555A (ko) | 다이어트용 보조식품 조성물 | |
CN115517369A (zh) | 保护心脑血管、提高免疫力的复合蛋白多肽粉及制备方法 | |
KR20110121246A (ko) | 비만개선 다이어트용 웰빙 한방식품 및 그 제조방법 | |
KR100363999B1 (ko) | 갱년기 이후 우울증 및 신경쇠약 개선 음료 조성물 및이의 제조방법 | |
CN109157548B (zh) | 一种具有抗疲劳和壮阳功能的组合物及制备方法 | |
CN111035017A (zh) | 一种防治肌肉流失的口服液 | |
CN112715961A (zh) | 一种有助于老年糖尿病人增肌的食品组合物 | |
KR101908850B1 (ko) | 구기자를 포함하는 항비만 한방조성물 및 그 제조방법 | |
CZ20022978A3 (cs) | Prostředek pro zlepšení syntézy mucinu | |
CN110235990A (zh) | 一种调节赛鸽飞翔体能的组合物 | |
KR20010097870A (ko) | 퇴행성관절염 개선 음료 조성물 및 이의 제조 방법 | |
KR100515923B1 (ko) | 바이오 복합 단백질 조성방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |